NASDAQ · KPTI
Healthcare · Biotechnology
$0.09
Down-$0.02 (-21.16%)
Updated Nov 4, 2026, 4:48 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · KPTI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
KPTI closed at $0.09 after 21 trading sessions, down 86.41% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.11 | $0.11 | $0.082 | $0.0883 | 16.88M |
| Nov 2, 2026 | $0.153 | $0.16 | $0.0946 | $0.112 | 47.45M |
| Oct 30, 2026 | $0.902 | $0.902 | $0.5842 | $0.662 | 3.52M |
| Oct 29, 2026 | $0.8097 | $0.9869 | $0.7807 | $0.8798 | 6.85M |
| Oct 28, 2026 | $0.456 | $0.9091 | $0.456 | $0.8321 | 55.29M |
| Oct 27, 2026 | $0.4592 | $0.4829 | $0.4305 | $0.48 | 996.61K |
| Oct 26, 2026 | $0.5084 | $0.5166 | $0.4224 | $0.4821 | 1.37M |
| Oct 23, 2026 | $0.5366 | $0.555 | $0.44 | $0.5175 | 1.96M |
| Oct 22, 2026 | $0.437 | $0.5526 | $0.4222 | $0.5461 | 7.49M |
| Oct 21, 2026 | $0.363 | $0.436 | $0.363 | $0.4244 | 1.62M |
| Oct 20, 2026 | $0.34 | $0.3892 | $0.34 | $0.3586 | 766.73K |
| Oct 19, 2026 | $0.40 | $0.40 | $0.3311 | $0.346 | 1.26M |
| Oct 16, 2026 | $0.3509 | $0.40 | $0.33 | $0.3901 | 2.71M |
| Oct 15, 2026 | $0.31 | $0.3522 | $0.31 | $0.3508 | 1.4M |
| Oct 14, 2026 | $0.4274 | $0.4274 | $0.315 | $0.315 | 2.08M |
| Oct 13, 2026 | $0.49 | $0.5016 | $0.3958 | $0.4274 | 1.75M |
| Oct 12, 2026 | $0.5937 | $0.6047 | $0.502 | $0.5051 | 898.61K |
| Oct 9, 2026 | $0.602 | $0.6254 | $0.565 | $0.605 | 963.11K |
| Oct 8, 2026 | $0.63 | $0.6438 | $0.60 | $0.60 | 870.98K |
| Oct 7, 2026 | $0.65 | $0.6896 | $0.6231 | $0.645 | 759.25K |
| Oct 6, 2026 | $0.6912 | $0.715 | $0.6351 | $0.6499 | 1.18M |
The latest Smart Investors Daily articles mentioning KPTI.
Company
Market Activity
Research & News
KPTI research
Company profile and research snapshot.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Rodman & Renshaw | Neutral | — |
| Jul 31, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | — |
| May 6, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Oct 22, 2026
As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and
Benzinga · Oct 14, 2026
As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to
Yahoo · Oct 1, 2026
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5
Yahoo · Sep 11, 2026
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KPTI.
